Gielda Papierów Wartosciowych w Warszawie S A : New listing of BIOCELTIX

The company BIOCELTIX S.A. ​​was newly listed on the GPW Main Market on 5 September 2022.
BIOCELTIX S.A. is the 420^th company listed on the Main Market and the fifth new listing on the Main Market in 2022.

Key information

* at the average price of the Company's shares in the NC ATS in the last three months before the submission of the application for admission, equal to PLN 34.96

Issuer's history and business

The legal predecessor of the Issuer, Pracelo Sp. z o.o., was founded in July 2016. In February 2018, the company changed its name to Bioceltix Sp. z o.o. The company's conversion into a joint-stock company was registered six months later.

The Company's shares were listed in the NewConnect ATS from 8 November 2021.

The company is active in the biotechnology sector, targeting the potential use of stem cells in the treatment of animals. Research and development work on potential innovative medicinal products covers common diseases in companion animals: dogs, horses, and cats. The objective is to obtain marketing authorisation for medicinal products approved by the relevant supervisory authorities, following proof of efficacy of the active ingredient and the possibility of manufacturing a standardised product with reproducible parameters.

As at the Prospectus Date, the Issuer is developing the following medicinal products:

• BCX-CM-J - for the treatment of osteoarthritic lesions of the joints in dogs by intra-articular injection,
• BCX-CM-AD - for the treatment of atopic dermatitis in dogs by intravenous injection,
• BCX-EM - for the treatment of arthritis in horses by intramuscular injection.

The Issuer's intention is to submit marketing authorisation applications for all the above products to the European Medicines Agency up to 2024. As at the date of the prospectus, the Company has 19 employees.

The Company did not conduct a public offering immediately prior to the admission of the shares to trading on the GOW Main Market. In 2020 and 2021, the Issuer conducted two public offerings of series F and G shares prior to listing on NewConnect, raising a total of nearly PLN 11 million.

The Company's share capital amounts to PLN 342,732.5 and is divided into 3,427,325 series A-I shares with a nominal value of PLN 0.1 each, including:

• 1,981,500 series A shares;
• 104,290 series B shares;
• 172,000 series C shares;
• 186,224 series D shares;
• 271,550 series E shares;
• 211,225 series F shares;
• 360,000 series G shares;
• 140,536 series I shares.

Company's shareholders

• Infini ASI Sp. z o.o. - 500,000 shares representing 14.59% of the share capital and total vote;
• Kvarko Group ASI Sp. z o.o. - 470,953 shares representing 13.74% of the share capital and total vote;
• Łukasz Bzdzion - 415,763 shares representing 12.13% of the share capital and total vote;
• Alternative Solution ASI S.A. - 256,832 shares representing 7.49% of the share capital and total vote;

Other shareholders - 1,783,777 shares representing 52.05% of the share capital and total vote.

Company capitalisation: PLN 120 million

at the average price of the Company's shares in the NC ATS in the last three months before the submission of the application for admission, equal to PLN 34.96

Issuer's selected financials:

*unaudited

Financial forecasts

The company has not published financial forecasts.

Newly introduced instruments:

• 1,981,500 series A shares;
• 104,290 series B shares;
• 172,000 series C shares;
• 186,224 series D shares;
• 271,550 series E shares;
• 211,225 series F shares;
• 360,000 series G shares.